XenoPort to Present at the 23rd Annual Piper Jaffray Health Care Conference
November 15 2011 - 10:00AM
Business Wire
XenoPort, Inc. (Nasdaq: XNPT) announced today
that it will provide access via the World Wide Web to its
presentation at the 23rd Annual Piper Jaffray Health Care
Conference. The live presentation will occur at 7:30 a.m. Pacific
Time (10:30 a.m. Eastern Time) on Wednesday, November 30, 2011. A
replay of the presentation will also be available.
To access the live presentation via the Web,
please go to www.XenoPort.com. Please connect to the Web site at
least 15 minutes prior to the live presentation to ensure adequate
time for any software downloads that may be necessary to listen to
the Webcast.
A replay of the Webcast can be accessed for a
minimum of one month and will be available approximately 24 hours
after the live presentation.
About XenoPort
XenoPort is a biopharmaceutical company focused
on developing and commercializing a portfolio of internally
discovered product candidates for the potential treatment of
neurological disorders. Horizant™ (gabapentin enacarbil)
Extended-Release Tablets is XenoPort’s first FDA-approved product.
GlaxoSmithKline holds commercialization rights and certain
development rights for gabapentin enacarbil in the United States.
Gabapentin enacarbil is also being developed in partnership with
Astellas Pharma Inc. for the potential treatment of restless legs
syndrome in Japan. XenoPort holds all other world-wide rights and
has co-promotion and certain development rights to gabapentin
enacarbil in the United States. XenoPort’s pipeline of product
candidates includes potential treatments for patients with
neuropathic pain, spasticity and Parkinson’s disease.
To learn more about XenoPort, please visit the
Web site at www.XenoPort.com.
XenoPort is a registered trademark of XenoPort,
Inc.
Horizant is a trademark of GlaxoSmithKline.
XNPT2G
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Apr 2023 to Apr 2024